Myeloid interferon-γ receptor deficiency does not affect atherosclerosis in LDLR-/- mice

Marieke C.S. Boshuizen, Annette E. Neele, Marion J.J. Gijbels, Saskia van der Velden, Marten A. Hoeksema, Ruth A. Forman, Werner Muller, Jan Van den Bossche, Menno P.J. de Winther

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)


Background and aims: Atherosclerosis is a chronic lipid-driven inflammatory disease of the arterial wall. Interferon gamma (IFNγ) is an important immunomodulatory cytokine and a known pro-atherosclerotic mediator. However, cell-specific targeting of IFNγ or its signaling in atherosclerosis development has not been studied yet. As macrophages are important IFNγ targets, we here addressed the involvement of myeloid IFNγ signaling in murine atherosclerosis. Methods: Bone marrow was isolated from interferon gamma receptor 2 chain (IFNγR2) wildtype and myeloid IFNγR2 deficient mice and injected into lethally irradiated LDLR-/- mice. After recovery mice were put on a high fat diet for 10 weeks after which atherosclerotic lesion analysis was performed. In addition, the accompanying liver inflammation was assessed. Results: Even though absence of myeloid IFNγ signaling attenuated the myeloid IFNγ response, no significant differences in atherosclerotic lesion size or phenotype were found. Also, when examining the liver inflammatory state no effects of IFNγR2 deficiency could be observed. Conclusion: Overall, our data argue against a role for myeloid IFNγR2 in atherosclerosis development. Since myeloid IFNγ signaling seems to be nonessential throughout atherogenesis, it is important to understand the mechanisms by which IFNγ acts in atherogenesis. In the future new studies should be performed considering other cell-specific targets.

Original languageEnglish
Pages (from-to)325-333
Number of pages9
Publication statusPublished - 1 Mar 2016


  • Atherosclerosis
  • Interferon gamma receptor
  • Macrophage
  • Mouse model

Cite this